NAD<sup>+</sup> sensing by PARP7 regulates the C/EBPβ-dependent transcription program during adipogenesis
Stokes MS., Kim YJ., Kim Y., Koul S., Chiu SP., Liu C.
Animal Study, published in Cell Rep (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cell Rep (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41621069
- PMCID
- PMC13032856
- DOI
- 10.1016/j.celrep.2026.116929
- Citations
- 1
Abstract (original English)
We identified poly(ADP-ribose) polymerase 7 (PARP7), a mono(ADP-ribosyl) transferase, as a regulator of C/EBPβ-dependent proadipogenic gene expression. PARP7 functions as a nuclear NAD + sensor; at higher nuclear NAD + concentrations in undifferentiated preadipocytes, PARP7 is catalytically active for auto-mono(ADP-ribosyl)ation (autoMARylation). As nuclear NAD + concentrations decline upon differentiation, autoMARylation decreases dramatically. AutoMARylation promotes instability of PARP7 through an E3 ligase-ubiquitin-proteasome pathway mediated by the ubiquitin E3 ligases DTX2 and RNF114, which ubiquitylate MARylated PARP7. Stabilized PARP7 serves as a coregulator of C/EBPβ by stimulating p300-mediated histone H3 lysine 27 acetylation and the binding of C/EBPβ across the genome. Genetic depletion of PARP7 in mice promotes decreased body weight in mice fed a high-fat diet, reduced fat mass, inhibition of adipogenesis during mammary gland involution, and a reduction in lipid synthesis. Collectively, our results extend the biology of PARP7 to adipogenesis and elucidate the molecular mechanisms underlying a PARP7-p300-H3K27ac-C/EBPβ pathway for proadipogenic gene regulation.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.